Anavex Life Sciences to Present at the Citizens Life Sciences Conference

Anavex Life Sciences (Nasdaq: AVXL) will present at the Citizens Life Sciences Conference.

Rhea-AI Summary

Anavex Life Sciences (Nasdaq: AVXL) will present at the Citizens Life Sciences Conference. Christopher U Missling, PhD, President & CEO, is scheduled to speak on Tuesday, March 10, 2026 at 11:55 AM ET.

The presentation covers company developments in clinical-stage CNS programs including Alzheimer’s, Parkinson’s, schizophrenia, Rett syndrome and other neurodegenerative and rare diseases.

Argus Mar 3 session

+3.53% close to close Open Argus

Details

News Market Reaction – AVXL

In the Mar 3 session, AVXL gained 3.53%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights another investor-relations event for AVXL, with management presenting a...

Analysis

This announcement highlights another investor-relations event for AVXL, with management presenting at the Citizens Life Sciences Conference on March 10, 2026 at 11:55 AM (ET). In recent months, conference appearances, governance additions, and clinical collaborations have complemented financial updates and an active SEC filing cadence. Investors may monitor how these outreach efforts support awareness of the company’s CNS pipeline and how future regulatory and financing disclosures interact with this communication strategy.

Key Figures

Conference date: March 10, 2026 Presentation time: 11:55 AM (ET)

Conference date

March 10, 2026

Citizens Life Sciences Conference presentation date

Presentation time

11:55 AM (ET)

Scheduled start time of AVXL presentation

Historical Context

5 past events · Latest: Feb 25

5 events

1. Feb 25

   Conference appearance

   24h Move

   +0.9%

   Announcement of TD Cowen health care conference presentation and webcast access.

2. Feb 23

   Board appointment

   24h Move

   +1.0%

   Appointment of experienced healthcare leader to strengthen Board governance.

3. Feb 09

   Earnings and update

   24h Move

   +6.1%

   Q1 2026 results with cash position and updates on CNS clinical programs.

4. Feb 03

   Earnings date set

   24h Move

   -2.9%

   Scheduling of Q1 2026 results release and investor call details.

5. Jan 13

   Clinical initiative

   24h Move

   +8.2%

   Participation in ACCESS-AD precision-medicine initiative for Alzheimer’s with blarcamesine.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

central nervous system (cns), rett syndrome

2 terms

central nervous system (cns) medical

"and other central nervous system (CNS) disorders, today announced that"

The central nervous system (CNS) is the part of the body that includes the brain and spinal cord, acting as the control center for processing information and directing actions. It is essential for coordinating all bodily functions, from movement to thinking. For investors, understanding the CNS is important because it illustrates how complex systems—like markets or organizations—rely on core components to operate smoothly.

rett syndrome medical

"rare diseases, including Rett syndrome, and other central nervous system"

A rare genetic disorder that disrupts normal brain development in young children, most commonly girls, leading to slowed growth, loss of purposeful hand use, repetitive hand movements, motor problems, speech loss, and cognitive and breathing irregularities. Investors watch it because its severity and few treatment options create clear medical need and potential markets for therapies; think of it as a broken traffic signal in the brain that, if fixed, could restore many downstream functions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Christopher U Missling, PhD, President & Chief Executive Officer, will present at the Citizens Life Sciences Conference on Tuesday, March 10^th, 2026 at 11:55 AM (ET).

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com

Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Anavex (AVXL) present at the Citizens Life Sciences Conference in 2026?

Anavex will present on Tuesday, March 10, 2026 at 11:55 AM ET. According to Anavex, Christopher U Missling, PhD, President & CEO, is the scheduled presenter discussing the company's clinical-stage CNS programs and development pipeline.

Who is representing Anavex (AVXL) at the March 10, 2026 Citizens Life Sciences Conference?

Christopher U Missling, PhD, President & CEO, will present for Anavex. According to Anavex, he will outline the company's focus on clinical-stage therapies for Alzheimer’s, Parkinson’s, schizophrenia, Rett syndrome, and other CNS and rare disorders.

What topics will Anavex (AVXL) cover at the Citizens Life Sciences Conference on March 10, 2026?

The presentation will cover Anavex's clinical-stage CNS programs and therapeutic areas. According to Anavex, topics include Alzheimer’s, Parkinson’s, schizophrenia, neurodevelopmental and neurodegenerative diseases, and Rett syndrome developments in the company's pipeline.

How can investors follow Anavex (AVXL) presentation at the Citizens Life Sciences Conference?

Investors should check the conference schedule and Anavex investor channels for access details. According to Anavex, the company announced the presentation timing; investors may use the conference's attendee resources or company communications for webcast or replay information.

Does Anavex (AVXL) announce any financial or clinical readouts with the March 10, 2026 presentation?

The announcement only confirms a presentation slot and speaker scheduling on March 10, 2026. According to Anavex, no specific financial figures or clinical readout details were provided in the presentation notice; further disclosures would be announced separately if applicable.